Core Insights - Oncotelic Therapeutics, in collaboration with the Brush and Key Foundation, published a peer-reviewed research article analyzing biomarkers in hepatocellular carcinoma (HCC) and pancreatic ductal adenocarcinoma (PDAC) [1][2] Group 1: Research Findings - The study focuses on two biomarkers, DNMT3A and GMPS, and their prognostic significance, which is influenced by immune composition, metabolic reprogramming, and innate immune sensing pathways [2] - The analysis integrated data from over 7,000 patients, highlighting the context-dependent nature of these biomarkers [2] Group 2: Educational Mission - The Brush and Key Foundation aims to mentor young scholars through hands-on research experiences, fostering critical thinking and professional development [3][5] - The publication reflects the foundation's commitment to bridging scientific inquiry with real-world research experience [3][5] Group 3: Author Insights - Dr. Drashya Shah, an intern supported by the Brush and Key Foundation, emphasized the value of mentorship in enhancing research quality and personal confidence [4] - Dr. Vuong Trieu noted the intersection of bioinformatics, translational oncology, and mentorship in generating scientific insights [4] - Dr. Wen-Han Chang highlighted the importance of considering tumor context when interpreting biomarkers [4] Group 4: Company Background - Oncotelic Therapeutics, originally founded as OXiGENE, Inc. in 1988, focuses on oncology drug development, particularly for rare pediatric cancers [6] - The company has a joint venture for Diffuse Intrinsic Pontine Glioma (DIPG) and is involved in developing treatments for various cancers and conditions, including Parkinson's Disease and erectile dysfunction [6][7][8]

Core Insights - Oncotelic Therapeutics, in collaboration with the Brush and Key Foundation, published a peer-reviewed research article analyzing biomarkers in hepatocellular carcinoma (HCC) and pancreatic ductal adenocarcinoma (PDAC) [1][2] Group 1: Research Findings - The study focuses on two biomarkers, DNMT3A and GMPS, and their prognostic significance in HCC and PDAC, highlighting that their relevance is context-dependent, influenced by immune composition and metabolic pathways [2] - The research integrates data from over 7,000 patients, providing a comprehensive analysis of survival outcomes and tumor microenvironment [2] Group 2: Educational Mission - The Brush and Key Foundation aims to mentor young scholars through hands-on research experiences, fostering critical thinking and professional development [3][5] - The collaborative environment of the foundation enhances the quality of research and builds confidence in young researchers [4] Group 3: Company Background - Oncotelic Therapeutics, established in 1988, focuses on oncology drug development, particularly for rare pediatric cancers and other malignancies [6] - The company has a joint venture for Diffuse Intrinsic Pontine Glioma (DIPG) and is developing treatments for various conditions, including Parkinson's Disease and erectile dysfunction [7][8]

Company Overview - Oncotelic Therapeutics, Inc. is a biopharmaceutical company focused on developing transformative medicines for cancer patients, utilizing its PDAOAI platform and expertise in nanomedicines and the tumor microenvironment [1][4] - The company has a special emphasis on rare pediatric cancers and holds rare pediatric designation for Diffuse Intrinsic Pontine Glioma (DIPG) through its joint venture [4] Recent Developments - Oncotelic will present at the 19th Annual Main Event on October 21, 2025, where CEO Vuong Trieu will discuss the company's progress and vision [1][3] - The lead program, Sapu, is a 45%-owned joint venture that is advancing in its nanomedicine platform, with key milestones in formulation optimization, regulatory engagement, and clinical trials [3] Event Details - The LD Micro Main Event XIX will take place from October 19 to 21, 2025, featuring around 120 companies presenting and engaging in one-on-one meetings with investors [3] - The event will include registration, keynote speakers, and company presentations over three days [3] Product Pipeline - Oncotelic has developed AL-101 for the intranasal delivery of apomorphine, targeting Parkinson's Disease, with over 60,000 new diagnoses annually in the U.S. and a projected increase to over 1.2 million patients by 2030 [5] - AL-101 is also being developed for Erectile Dysfunction (ED) and Female Sexual Dysfunction (FSD), addressing significant unmet medical needs in these areas [5][6]

Core Insights - Oncotelic Therapeutics is advancing the evaluation of OT-101, an investigational antisense oligonucleotide targeting TGFB2, as a potential treatment for pancreatic ductal adenocarcinoma (PDAC) [1][5] - New research indicates that TGFB2 expression and methylation may serve as prognostic markers for overall survival in PDAC patients, particularly in younger cohorts [1][2][3] Company Overview - Oncotelic Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing RNA-targeted and small-molecule therapeutics for cancer and rare diseases [1][6] - The company has a 45% ownership interest in Sapu Biosciences, which contributed to the recent research publication [1] Research Findings - The study published in the International Journal of Molecular Sciences highlights that high TGFB2 expression correlates with reduced overall survival in patients under 65 years old, with median overall survival of 17.9 months for high TGFB2 expression compared to 66.9 months for low expression [3] - Elevated TGFB2 methylation is associated with improved survival in younger patients, with median overall survival of 66.9 months for high methylation versus 17.9 months for low methylation [3] - Clinical data from the OT-101 P001 PDAC study suggests that targeting TGFB2 is particularly beneficial for younger patients, with a median overall survival of 12.7 months in a treated subset characterized by low IL-6 [2] Market Context - The incidence of PDAC is increasing among younger adults, with approximately 4% annual growth in the 15-34 age bracket, while the five-year survival rate for all PDAC patients is only around 12% [4] - The findings underscore the need for targeted therapies like OT-101 to address the grim outcomes faced by younger PDAC patients [4]